Voyager Therapeutics Inc (VYGR) Insider Bernard Ravina Sells 3,630 Shares

Voyager Therapeutics Inc (NASDAQ:VYGR) insider Bernard Ravina sold 3,630 shares of the business’s stock in a transaction that occurred on Wednesday, January 10th. The stock was sold at an average price of $16.40, for a total transaction of $59,532.00. Following the completion of the transaction, the insider now directly owns 7,353 shares of the company’s stock, valued at approximately $120,589.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Bernard Ravina also recently made the following trade(s):

  • On Monday, December 11th, Bernard Ravina sold 5,490 shares of Voyager Therapeutics stock. The stock was sold at an average price of $13.63, for a total transaction of $74,828.70.
  • On Friday, November 10th, Bernard Ravina sold 5,490 shares of Voyager Therapeutics stock. The stock was sold at an average price of $13.26, for a total transaction of $72,797.40.

Voyager Therapeutics Inc (NASDAQ VYGR) opened at $18.38 on Friday. Voyager Therapeutics Inc has a 1-year low of $8.10 and a 1-year high of $25.99. The stock has a market cap of $495.33 and a price-to-earnings ratio of -6.47.

A number of equities analysts recently commented on the stock. Zacks Investment Research raised shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 6th. BidaskClub raised shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, January 5th. BTIG Research initiated coverage on shares of Voyager Therapeutics in a report on Tuesday, December 19th. They issued a “buy” rating and a $32.00 price target on the stock. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $28.00 price target on shares of Voyager Therapeutics in a report on Tuesday, November 28th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $26.00 price target (up from $22.00) on shares of Voyager Therapeutics in a report on Monday, November 20th. One research analyst has rated the stock with a sell rating, two have given a hold rating and twelve have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $26.90.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Iguana Healthcare Management LLC purchased a new stake in shares of Voyager Therapeutics during the third quarter valued at $515,000. Point72 Asset Management L.P. purchased a new stake in shares of Voyager Therapeutics during the third quarter valued at $2,695,000. Dimensional Fund Advisors LP grew its holdings in shares of Voyager Therapeutics by 7.9% during the third quarter. Dimensional Fund Advisors LP now owns 105,914 shares of the company’s stock valued at $2,181,000 after buying an additional 7,786 shares during the last quarter. Schwab Charles Investment Management Inc. grew its holdings in shares of Voyager Therapeutics by 71.5% during the third quarter. Schwab Charles Investment Management Inc. now owns 49,788 shares of the company’s stock valued at $1,026,000 after buying an additional 20,753 shares during the last quarter. Finally, Mckinley Capital Management LLC Delaware purchased a new stake in shares of Voyager Therapeutics during the third quarter valued at $1,412,000. 35.97% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Voyager Therapeutics Inc (VYGR) Insider Bernard Ravina Sells 3,630 Shares” was originally published by Stock Observer and is the property of of Stock Observer. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.thestockobserver.com/2018/01/14/voyager-therapeutics-inc-vygr-insider-bernard-ravina-sells-3630-shares.html.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply